<DOC>
	<DOCNO>NCT01811550</DOCNO>
	<brief_summary>The Insights Selected Procoagulation Markers Outcomes Stroke Trial ( I-SPOT ) : Response Insulin Administration Blood Glucose Control proposal design accompany Stroke Hyperglycemia Insulin Network Effort ( SHINE ) clinical trial , Phase III multicenter , randomize , control trial planning determine efficacy validate safety glycemic control stroke patient . The SHINE trial recruit 1,400 AIS patient Type II diabetes mellitus ( T2DM ) hyperglycemia , receive 3 day hyperglycemia control intravenous ( IV ) insulin therapy control therapy subcutaneous ( SQ ) insulin . The I-SPOT trial recruit 315 SHINE patient . Blood coagulation marker level measure 48 hour start treatment . Baseline temporal change biomarkers level compare treatment group . Hypothesis : The decrease level marker blood coagulation great patient treat IV insulin reduce BG patient treat SQ Insulin standard fashion . Hypothesis : The decrease level marker blood coagulation great patient without favorable ( SHINE ) outcome ( defined baseline stroke severity adjust measure functional ability 90 day AIS ) . Hypothesis : Hyperglycemia control modulate relationship blood coagulation level functional outcome T2DM patient stroke . Patients treat IV Insulin hyperglycemia control favorable ( SHINE ) outcome great decrease blood coagulation level either IV Insulin-treated patient without favorable outcome SQ Insulin-treated without favorable outcome 90 day AIS .</brief_summary>
	<brief_title>Study Procoagulation Markers Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<criteria>Enrolled SHINE study Ability give Informed Consent ( self LAR ) Current plan use full dose anticoagulation baseline 48 hour sample collection Known moderate severe hepatic insufficiency ( define INR &gt; 1.5 know history variceal bleed hepatic encephalopathy ) Prior concurrent thrombotic hypercoagulable condition ( Antiphospholipid antibody syndrome ; Antithrombin III , Protein C S deficiency ; Congenital Inherited Factor deficiency ; sickle cell disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>